Tag: FDA

63 posts found

Marijuana Continues to Take Major Steps Forward

Congress may soon clear federal restrictions to processing marijuana transactions, while the FDA asks for feedback on handling marijuana products.

Phase 3 clinical trials for this non-opioid drug demonstrate significant reductions in pain for osteoarthritis and chronic low-back pain.

Federal lawmakers and administrative agencies continue to investigate how to best lower ever-increasing drug prices.

Can special implants in the brain override paralysis? The FDA believes one day they could.

The FDA created special drug labels to clear a development hurdle and encourage manufacturers.

The opioid prodrug for acute pain will soon be available in both a stronger and weaker dose.

Will doctors one day prescribe apps meant to drive behavior changes instead of drugs?

The reSET-O app uses cognitive behavioral therapy techniques to assist patients engaged in medication-assisted therapy for opioid dependence.

Five-to-ten times stronger than fentanyl, this drug is not for consumer use, and many claim it could worsen the opioid crisis.

Cassipa (buprenorphine and naloxone) sublingual film delivers a new dosage for the treatment of opioid dependence.

The FDA is working to create new opioid prescribing practices and guidelines, while also shifting drug development priorities for pain medications.

Healthesystems’ Chief Medical Officer spoke with WorkCompCentral regarding DEA plans to reduce opioid manufacturing.

Drugs to treat opioid dependence could be approved under new clinical endpoints other than reducing opioid use.

The FDA recently approved drugs to treat opioid dependence, migraines, and rheumatoid arthritis.

A newly released draft guidance encourages the development of more sustained-release buprenorphine products.

Prev 1 2 3 4 5 Next